Status:
UNKNOWN
Mesenchymal Stem Cell Therapy for Type 1 Diabetes Mellitus Patients
Lead Sponsor:
Van Hanh General Hospital
Collaborating Sponsors:
University of Science Ho Chi Minh City
Conditions:
Type 1 Diabetes Mellitus
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) transplantation for type 1 Diabetes Mellitus patients.
Detailed Description
Mesenchymal stem cells (MSCs) are collected from autologous bone marrow mononuclear cells and allogeneic umbilical cord tissue (UC-MSC). 15 patients with type 1 Diabetes Mellitus will be enrolled and...
Eligibility Criteria
Inclusion
- Who is diagnosed with Type 1 Diabetes Mellitus according to the ADA, the patients meet at least one of the following criteria:
- At least one autoantibody associated with Type 1 Diabetes Mellitus such as ICA or GAD.
- Previously diagnosed at a medical facility with Type 1 Diabetes.
- Having evidence of insulin depletion based on the test results during screening.
- Patients treated with fixed insulin dose for at least 3 months.
- Males and females between age 18 and 45 years at the screening.
- Patients able to read, write and understand ICF form
Exclusion
- Uncontrolled blood pressure at the time of enrollment: systolic pressure \>160 mmHg and/or diastolic blood pressure \> 100 mmHg.
- Having evidence related to renal dysfunction:
- creatinine \> 1.5 mg/dl or (\>133 mmol/L) for men.
- creatinine \> 1.4 mg/dl or (\>124 mmol/L) for woman.
- eGRF \< 40 ml/ min
- Proteinuria \> 300 mg/day
- Having evidence of ketoacidosis at the time of selection.
- Having evidence of ongoing or frequent hypoglycemia.
- Having severe infection
- Infected with hepatitis B virus or hepatitis C or tuberculosis. Positive results of HbsAg or Anti HCV or/and PCR tuberculosis are only acceptable in case of vaccination and without suspicious signs. All other cases are not accepted even in the absence of clinical signs.
- Diseases detected before/during screening such as cardiovascular disease, respiratory disease ( pulmonary, fibrosis, chronic respiratory failure), liver disease, cancer, neurology, metabolism.
- Having abnormalities in red blood cells such as sickle cells disease.
- Using alcohol and/or tobacco.
- Blood clotting disorders (INR \> 1.5, PTT \>40, PT \> 15).
- Taking any anticoagulant.
- Taking systemic steroids.
- Participate in another clinical study involving experimenting drugs and/or medical equipment.
- Patients who are unable to perform the tests and assessments needed for the study (eg, patients who are unable to perform bone marrow transplantation) or patients who do not agree to participate in the study.
Key Trial Info
Start Date :
April 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2018
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT03484741
Start Date
April 1 2017
End Date
November 1 2018
Last Update
April 4 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Van Hanh Geral Hospital
Ho Chi Minh City, Ho Chi Minh, Vietnam, 700000